High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients

Abstract

Background and Objectives: Human parvovirus B19 is a potential risk to hemophiliac patients receiving blood products. Materials and Methods: To determine the prevalence of the corresponding antibody in patients with hemophilia A or B or von Willebrand’s disease, we tested 326 hemophilia patients for anti-B19 IgG. The results were compared with those of 203 age-matched controls (male blood donors and children). Results: The overall prevalence of B19 IgG in the hemophilia patients was 302/326, and in the controls 123/203. Below the age of 10, hemophilia patients had a higher prevalence of B19 IgG (76%, 42/55) than the controls (23%, 11/48; p < 0.00001). In those below the age of 5 who had been treated exclusively with monoclonally purified concentrate, it made no difference whether the product was pasteurized or solvent-detergent treated. There was a significantly lower incidence in patients who were rarely treated. Conclusion: Parvovirus B19 is frequently transmitted in blood products. Existing virus-inactivating methods do not prevent transmission.

Prevalence of Human Parvovirus B19 DNA and IgG&sol;IgM Antibodies in Polish Haemophilia Patients

“…The anti–B19 IgG frequency in Polish patients was similar to that found by others [3, 4], but slightly lower than that recently observed among Dutch haemophiliacs [2]. Also the frequency of antibodies in Polish blood donors was lower than in the Dutch study [2], especially if results within similar age groups are compared.…”

“…Also the frequency of antibodies in Polish blood donors was lower than in the Dutch study [2], especially if results within similar age groups are compared. This difference may reflect lower sensitivity of the assay used for our study.…”

“…We have read with interest two papers on the high prevalence of antibodies to human parvovirus B19 in patients with haemophilia or other congenital coagulation disorders, recently published in Vox Sanguinis [2, 3]. We would like to share our experience in this respect.…”

Safety and efficacy of a plasma‐derived monoclonal purified factor VIII concentrate during 10 years of follow‐up

“…We could not evaluate hepatitis A virus (HAV) transmission as all HAV antibody negative patients were vaccinated during the last decade. Neither was examination of Parvovirus B19 transmission possible because of the pre-existing high prevalence of this virus among PTPs [12]. Future transmission of as yet unknown viruses or variant Creutzfeldt-Jakob disease remains theoretically possible [13].…”

Quantitative real‐time detection of parvovirus B19 DNA in plasma

“…Although parvovirus B19 (B19V) is normally transmitted via the respiratory route, transmission via the administration of blood products has been reported 1‐6 . Several plasma derivatives are prepared from large plasma pools.…”